Home Immunity AstraZeneca’s Covid Vaccine Immunity Wanes After 3 Months, Lancet Study Finds, World News

AstraZeneca’s Covid Vaccine Immunity Wanes After 3 Months, Lancet Study Finds, World News



A study published by The Lancet found that the immunity offered by AstraZeneca-Oxford’s COVID-19 vaccine wanes three months after receiving two doses, underscoring the importance of booster shots.

The results were based on data from two million people in Scotland and 42 million people in Brazil who were vaccinated with the AstraZeneca vaccine, known as Covishield in India.

Analyzing data from Scotland, researchers found that there was around five times the chance of being hospitalized or dying from COVID-19 almost five months after being double vaccinated.

The drop in effectiveness begins to appear around three months, when the risk of hospitalization and death is double that of two weeks after the second dose, they said.

Read also | Omicron gradually spreads in India: 200 cases detected so far, government says

Researchers in Scotland and Brazil found that the risk of hospitalization and death increased threefold in less than four months after the second dose of the vaccine. Similar figures were seen for Brazil, they said.

“Vaccines have been a key tool in the fight against the pandemic, but declining effectiveness has been a concern for some time,” said Professor Aziz Sheikh, University of Edinburgh, UK.

“By identifying when the decline begins to occur in the Oxford-AstraZeneca vaccine, it should be possible for governments to design booster programs that can ensure maximum protection is maintained,” Sheikh said.

Read also | Israel announces fourth booster dose for over 60s and medics as Omicron rages

The team was able to compare the data between Scotland and Brazil as they had a similar interval between doses – 12 weeks – and the initial prioritization of those vaccinated – those most at risk of serious illness and workers in the health.

The dominant variant was different in each country during the study period – Delta in Scotland and Gamma in Brazil.

This means that the drop in effectiveness is likely due to the shrinking vaccine and the impact of the variants, the researchers said.

However, experts have warned that these numbers should be treated with caution as it becomes increasingly difficult to compare unvaccinated people with those vaccinated with similar characteristics, especially among older age groups where so many people are now vaccinated.

(With contributions from agencies)